Amedisys, Inc. (NASDAQ:AMED) Receives Consensus Rating of "Hold" from Brokerages

Shares of Amedisys, Inc. (NASDAQ:AMED - Get Free Report) have been assigned an average recommendation of "Hold" from the five brokerages that are currently covering the company, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 12 month target price among brokers that have covered the stock in the last year is $100.67.

A number of research analysts recently weighed in on the stock. Cantor Fitzgerald reiterated a "neutral" rating and issued a $101.00 price objective on shares of Amedisys in a report on Thursday, July 25th. William Blair cut shares of Amedisys from an "outperform" rating to a "market perform" rating in a research report on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft cut shares of Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price target for the company. in a research report on Monday, July 29th.

Institutional Trading of Amedisys

A number of institutional investors have recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise acquired a new position in Amedisys during the 1st quarter worth about $60,000. Innealta Capital LLC bought a new stake in Amedisys during the 2nd quarter worth approximately $64,000. Covestor Ltd boosted its position in Amedisys by 134.2% during the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider's stock worth $72,000 after acquiring an additional 447 shares during the last quarter. Signaturefd LLC boosted its position in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider's stock worth $104,000 after acquiring an additional 530 shares during the last quarter. Finally, Mesirow Institutional Investment Management Inc. boosted its holdings in shares of Amedisys by 9.9% in the 4th quarter. Mesirow Institutional Investment Management Inc. now owns 2,844 shares of the health services provider's stock valued at $270,000 after buying an additional 257 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Amedisys Trading Up 0.0 %

Shares of NASDAQ:AMED traded up $0.02 during trading hours on Friday, hitting $97.17. 495,022 shares of the company's stock traded hands, compared to its average volume of 328,482. Amedisys has a 1 year low of $89.55 and a 1 year high of $98.95. The business has a fifty day moving average price of $97.64 and a 200-day moving average price of $94.55. The firm has a market capitalization of $3.18 billion, a P/E ratio of -151.73, a price-to-earnings-growth ratio of 1.92 and a beta of 0.79. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.16 and a quick ratio of 1.16.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings results on Wednesday, July 24th. The health services provider reported $1.32 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.10. The business had revenue of $591.19 million for the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a return on equity of 12.39% and a net margin of 4.02%. Equities analysts expect that Amedisys will post 4.66 earnings per share for the current year.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.